{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T05:26:52Z","timestamp":1781155612540,"version":"3.54.1"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,12,3]],"date-time":"2024-12-03T00:00:00Z","timestamp":1733184000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Osteogenesis imperfecta (OI) is a congenital skeletal disorder characterized by bone fragility. Bisphosphonates (BISs) have become the mainstream treatment in children with OI. However, an optimal treatment protocol has not yet been established, while BIS treatment tends to be administered to normalize bone mineral density (BMD). Bone quality is an important component of bone strength. The trabecular bone score (TBS) is a quantitative measure of the microstructure that affects bone quality. This study investigated the TBS during BIS treatment in children with OI.<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and methods<\/jats:title><jats:p>Twenty-nine children with OI were enrolled and classified into two groups: mild (type 1) and moderate to severe (types 3 and 4). Dual-energy x-ray absorptiometry images were retrospectively analyzed for TBS calculation. The relationship between the areal BMD (aBMD), its Z-score, height-adjusted BMD (BMD<jats:sub>HAZ<\/jats:sub>) Z-score, TBS, and TBS Z-score with the treatment duration was assessed for each group.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In the mild group, the aBMD, its Z-score, and BMDHAZ Z-score showed a significant positive correlation with treatment duration (r\u2009=\u20090.68, 0.68, 0.72, respectively, <jats:italic>p<\/jats:italic>\u2009&amp;lt;\u20090.01). The TBS Z-score tended to increase with treatment duration, albeit without reaching significance. In the moderate to severe group, the TBS Z-score showed a significant positive correlation with treatment duration (r\u2009=\u20090.48, <jats:italic>p<\/jats:italic>\u2009&amp;lt;\u20090.01), in contrast to the aBMD Z-score, which did not increase. Finally, the BMDHAZ Z-score only showed a weak positive correlation with treatment duration (r\u2009=\u20090.37, <jats:italic>p<\/jats:italic>\u2009&amp;lt;\u20090.01).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Because BIS affect the BMD and TBS differently based on the severity of OI, treatment goals may need to be stratified by disease severity.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fped.2024.1500023","type":"journal-article","created":{"date-parts":[[2024,12,3]],"date-time":"2024-12-03T04:22:31Z","timestamp":1733199751000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Trabecular bone scores in children with osteogenesis imperfecta respond differently to bisphosphonate treatment depending on disease severity"],"prefix":"10.3389","volume":"12","author":[{"given":"Natsuko","family":"Futagawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosei","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Miyahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirokazu","family":"Tsukahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,12,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1002\/ajmg.a.63132","article-title":"Nosology of genetic skeletal disorders: 2023 revision","volume":"191","author":"Unger","year":"2023","journal-title":"Am J Med Genet A"},{"key":"B2","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1136\/jmg.16.2.101","article-title":"Genetic heterogeneity in osteogenesis imperfecta","volume":"16","author":"Sillence","year":"1979","journal-title":"J Med Genet"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1002\/ajmg.a.36545","article-title":"Osteogenesis imperfecta: clinical diagnosis, nomenclature and severity assessment","author":"Van Dijk","year":"2014","journal-title":"Am J Med Genet A"},{"key":"B4","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.ajhg.2012.06.005","article-title":"A single recurrent mutation in the 5'-UTR of IFITM5 causes osteogenesis imperfecta type V","volume":"91","author":"Cho","year":"2012","journal-title":"Am J Hum Genet"},{"key":"B5","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.ajhg.2012.06.011","article-title":"A mutation in the 5'-UTR of IFITM5 creates an in-frame start codon and causes autosomal-dominant osteogenesis imperfecta type V with hyperplastic callus","volume":"91","author":"Semler","year":"2012","journal-title":"Am J Hum Genet"},{"key":"B6","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1056\/NEJM199810013391402","article-title":"Cyclic administration of pamidronate in children with severe osteogenesis imperfecta","volume":"339","author":"Glorieux","year":"1998","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1111\/j.1442-200X.2008.02649.x","article-title":"Growth of infants with osteogenesis imperfecta treated with bisphosphonate","volume":"51","author":"Hasegawa","year":"2009","journal-title":"Pediatr Int"},{"key":"B8","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1210\/jc.2002-021371","article-title":"Osteogenesis imperfecta types I, III, and IV: effect of pamidronate therapy on bone and mineral metabolism","volume":"88","author":"Rauch","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"B9","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1001\/jama.285.6.785","article-title":"Osteoporosis prevention, diagnosis, and therapy","volume":"285","year":"2001","journal-title":"JAMA"},{"key":"B10","first-page":"216","article-title":"Normative data for lumbar spine bone mineral content in children: influence of age, height, weight, and pubertal stage","volume":"32","author":"De Schepper","year":"1991","journal-title":"J Nucl Med"},{"key":"B11","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s00247-006-0153-y","article-title":"Pediatric DXA: technique and interpretation","volume":"37","author":"Binkovitz","year":"2007","journal-title":"Pediatr Radiol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1002\/jbmr.2176","article-title":"Trabecular bone score: a noninvasive analytical method based upon the DXA image","volume":"29","author":"Silva","year":"2014","journal-title":"J Bone Miner Res"},{"key":"B13","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1210\/jc.2012-3118","article-title":"Manitoba Bone density P. TBS (trabecular bone score) and diabetes-related fracture risk","volume":"98","author":"Leslie","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"B14","doi-asserted-by":"publisher","first-page":"3436","DOI":"10.1210\/jc.2015-2002","article-title":"Spinal bone texture assessed by trabecular bone score in adolescent girls with anorexia Nervosa","volume":"100","author":"Donaldson","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"B15","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1002\/jbmr.4520","article-title":"Trabecular bone score reference values for children and adolescents according to age, sex, and ancestry","volume":"37","author":"Kalkwarf","year":"2022","journal-title":"J Bone Miner Res"},{"key":"B16","doi-asserted-by":"publisher","first-page":"CD005088","DOI":"10.1002\/14651858.CD005088.pub4","article-title":"Bisphosphonate therapy for osteogenesis imperfecta","volume":"10","author":"Dwan","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"B17","doi-asserted-by":"publisher","first-page":"2272","DOI":"10.1210\/jc.2012-1027","article-title":"Benefits and risks of bisphosphonate therapy for osteoporosis","volume":"97","author":"Khosla","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"B18","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/s00198-007-0533-7","article-title":"Bisphosphonates alter trabecular bone collagen cross-linking and isomerization in beagle dog vertebra","volume":"19","author":"Allen","year":"2008","journal-title":"Osteoporos Int"},{"key":"B19","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1016\/j.bone.2006.04.028","article-title":"Alterations in canine vertebral bone turnover, microdamage accumulation, and biomechanical properties following 1-year treatment with clinical treatment doses of risedronate or alendronate","volume":"39","author":"Allen","year":"2006","journal-title":"Bone"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1210\/jc.2016-3745","article-title":"Bisphosphonate treatment and the characteristics of femoral fractures in children with osteogenesis Imperfecta","volume":"102","author":"Vuorimies","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"B21","article-title":"Excel-based Clinical Tools for Growth Evaluation of Children.","year":""},{"key":"B22","doi-asserted-by":"publisher","first-page":"e1675","DOI":"10.1002\/mgg3.1675","article-title":"Genetic analysis in Japanese patients with osteogenesis imperfecta: genotype and phenotype spectra in 96 probands","volume":"9","author":"Higuchi","year":"2021","journal-title":"Mol Genet Genomic Med"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1210\/jc.2009-2057","article-title":"Height adjustment in assessing dual energy x-ray absorptiometry measurements of bone mass and density in children","volume":"95","author":"Zemel","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"B24","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1007\/s00198-023-06817-4","article-title":"Update on the clinical use of trabecular bone score (TBS) in the management of osteoporosis: results of an expert group meeting organized by the European Society for clinical and economic aspects of osteoporosis, osteoarthritis and musculoskeletal diseases (ESCEO), and the international osteoporosis foundation (IOF) under the auspices of WHO collaborating center for epidemiology of musculoskeletal health and aging","volume":"34","author":"Shevroja","year":"2023","journal-title":"Osteoporos Int"},{"key":"B26","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.jocd.2018.09.001","article-title":"TBS As a tool to differentiate the impact of antiresorptives onCortical and trabecular bone in children with OsteogenesisImperfecta","volume":"22","author":"Rehberg","year":"2019","journal-title":"J Clin Densitom"},{"key":"B27","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/S8756-3282(00)00269-6","article-title":"Static and dynamic bone histomorphometry in children with osteogenesis imperfecta","volume":"26","author":"Rauch","year":"2000","journal-title":"Bone"},{"key":"B28","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.1007\/s00198-015-3156-4","article-title":"Bone structure assessed by HR-pQCT, TBS and DXL in adult patients with different types of osteogenesis imperfecta","volume":"26","author":"Kocijan","year":"2015","journal-title":"Osteoporos Int"},{"key":"B29","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1056\/NEJMoa1916525","article-title":"Atypical femur fracture risk versus fragility fracture prevention with bisphosphonates","volume":"383","author":"Black","year":"2020","journal-title":"N Engl J Med"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1056\/NEJMc0707493","article-title":"Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate","volume":"358","author":"Lenart","year":"2008","journal-title":"N Engl J Med"},{"key":"B31","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1056\/NEJMoa023110","article-title":"Bisphosphonate-induced osteopetrosis","volume":"349","author":"Whyte","year":"2003","journal-title":"N Engl J Med"}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2024.1500023\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,3]],"date-time":"2024-12-03T04:22:36Z","timestamp":1733199756000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2024.1500023\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,3]]},"references-count":31,"alternative-id":["10.3389\/fped.2024.1500023"],"URL":"https:\/\/doi.org\/10.3389\/fped.2024.1500023","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,3]]},"article-number":"1500023"}}